Bevacizumab, bleeding, thrombosis, and warfarin.
Kilickap
Saadettin
S
Abali
Huseyin
H
Celik
Ismail
I
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D016228:Endothelial Growth Factors / Q000276:immunology*; D005472:Fluorouracil / Q000008:administration & dosage; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology*; D002955:Leucovorin / Q000008:administration & dosage; D008222:Lymphokines / Q000276:immunology*; D009362:Neoplasm Metastasis; D013927:Thrombosis / Q000139:chemically induced* / Q000517:prevention & control*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014859:Warfarin / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; D014859:Warfarin; D002955:Leucovorin; D005472:Fluorouracil